Outcomes of a specialty pharmacy program for oral oncology medications

American Journal of Pharmacy Benefits

Volumn 4, Issue 4, 2012, Pages 165-174

  Tschida, Suzanne J ^a   Aslam, Saad ^a   Lal, Lincy S ^a   Khan, Tanvir T ^a   Shrank, William H ^b   Bhattarai, Gandhi R ^a   Montague Clouse, Jon C ^a   Sahli, Brett D ^a   Newcomer, Lee N ^c  

^a OPTUM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c United Health Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; IMATINIB; LENALIDOMIDE; SORAFENIB;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CANCER THERAPY; COHORT ANALYSIS; EMERGENCY WARD; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SPECIALTY PHARMACY PROGRAM;

EID: 84865372540     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care. 2006;12(1) (suppl):S3-S16; quiz S17-S19.
2. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm. 2007;64(9)(suppl 5):S4-S7.
3. Curtiss FR. Pharmacy benefi t spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12(7):570-577.
4. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652-661.
5. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56-66.
6. Lal LS, Hung F, Feng C, et al. Evaluation of medication compliance in patients on antidepressants at an outpatient tertiary cancer center setting. J Oncol Pharm Pract. 2011;17(2):131-135.
7. Butow P, Palmer S, Pai A, et al. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4800-4809.
8. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and nonadherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25(6):481-496.
9. Noens L, van Lierde M, Bock R, et al. Prevalence, determinants and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-5411.
10. Marin D, Bazeos A, Mahon F, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14): 2381-2388.
11. Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7(3) (suppl):46s-51s
12. Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010;153(10):633-640.
13. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-658.
14. Holcombe, DG. Is oncology compatible with specialty pharmacy? Commun Oncol. 2005;2(2):173-181.
15. Cohen SM, Kwasny MJ, Ahn J. Use of specialty care versus standard retail pharmacies for treatment of hepatitis C. Ann Pharmacother. 2009;43(2): 202-209.
16. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Managed Care Pharm. 2006;12(9):735-744.
17. Stern D. Benefi t design innovations to managed specialty pharmaceuticals. J Managed Care Pharm. 2008;14(4)(suppl):S12-S16.
18. Tegenu, M. Health plan approach to operationalizing a specialty drug management program. J Managed Care Pharm. 2008;14(4)(suppl):S17-S21.
19. Rosenbaum PR, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
20. Dehejia RH, Vahba S. Propensity score-matching methods for non-experimental causal studies. Rev Econ Stat. 2002;84(1):151-161.
21. Zhao Z. Using matching to estimate treatment effects: data requirements, matching metrics, and Monte Carlo evidence. Rev Econ Stat. 2004;86(1):91-107.
22. Heckman JJ, Navarro-Lozano S. Using matching, instrumental variables and control functions to estimate economic choice models. NBER Working Paper No. 9497. Published 2003
23. Card D, Krueger AB. Minimum wages and employment: a case study of the fast-food industry in New Jersey and Pennsylvania. Am Econ Rev. 1994;84(4): 772-793.
24. Fu AZ, Dow WH, Liu G. Propensity score and difference-in-difference methods: a study of second-generation antidepressant use in patients with bipolar disorder. Health Services and Outcomes Research Methodology. 2007;7(1-2): 23-38.
25. Parsons LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Paper presented at: The SAS User Group International (SUGI 26) conference; April 22-25, 2001; Long Beach, CA. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed November 6, 2010
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitutional studies: development and validation. J Chron Dis. 1987; 40:373-383.
27. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analysis for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524-3530.
28. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546-550.
29. Shafazand S, Yang Y, Amore E, O'Neal W, Brixner D. A retrospective, observational cohort analysis of a nationwide database to compare heart failure prescriptions and related health care utilization before and after publication of updated treatment guidelines in the United States. Clin Ther. 2010;32(9):1642-1650.
30. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;10(2): 144-151.
31. Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defi ning, reporting, and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report- Part 1. Value Health. 2009;12(8):1044-1052.